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Currently, there is no cure for the treatment of spinal muscular atrophy (SMA). Based on the available clinical and molecular 
findings, different therapeutic strategies were tested in vitro and in vivo and clinical trials are ongoing. The main therapeutic direction 
is focused on the enhancement of SMN expression by increasing the full-length (fl) SMN2 transcript levels, preventing the SMN exon 
7 from skipping or from protein stabilizing. In addition, the action of neurotrophic, neuroprotective or anabolic agents is tested and 
stem cell and gene therapy approaches are in a promising development. 
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Introduction 
Spinal muscular atrophy is the second most 
common lethal autosomal recessive disorder in 
Caucasians, after cystic fibrosis [1,2]. The disease is 
characterized by the progressive degeneration of the 
alpha motoneurons, which leads to muscle atrophy, 
paralysis and even death [3]. Several clinical types were 
described for SMA, according to the age onset and the 
progression of the symptoms. The most recent 
classification [4] includes four types: type I (Werdning-
Hoffman), type II (intermediate), type III (Kugeleberg – 
Welander) and type IV (adult form). Type I is the most 
severe form, with an onset before the age of 6 months and 
a life expectation of around 2 years. Types II and III are 
known as chronic forms and are less severe, with an 
onset between 6-18 months (type II) and respectively after 
18 months (for type III). In many cases, Type IV mimics 
the symptoms of type III, but the onset is typically around 
30 years old. A normal life expectancy is characteristic for 
this adult form. Some research studies also reported the 
existence of type 0 or embryonic form, which is 
characterized by reduced movement of the fetus between 
30-36 weeks of the pregnancy and a very short life 
expectancy [5].   
The SMA determining gene, termed survival motor 
neuron (SMN1) was mapped on 5q11.2-13.3 region [6]. 
The homozygous deletion of SMN1 exon 7 is the most 
common mutation found in SMA patients, but there are 
also many cases of compound heterozygous subjects, for 
whom deletions and different point mutations have been 
detected. The SMN1 paralog and SMN2, differ with a 
single nucleotide in exon 7 (C-T), that alters the splicing 
process. A few models were proposed in order to explain 
this mechanism. The first hypothesis sustains the 
existence of an Exonic Splicing Enhancer (ESE) in SMN1 
gene, known as a binding site for splicing regulatory 
factors like arginine/serine rich (SR) protein. In SMN2 
gene, the T nucleotide in position 6 of exon 7 disrupts this 
ESE and, in an implicit way, the binding of the SR protein 
[7,8,9,10]. Another model proposed the existence of an 
Exonic Splicing Silencer only in SMN2 gene, which is a 
binding site for the hnRNP A1 repressor protein [11]. An 
extended analysis of these two models confirm the first 
one and sustain the role of hnRNP A1 protein in exon 7 
skipping, but for both genes, not only for the SMN2. A new 
hypothesis emerged from these observations sustains that 
the hnRNP A1 protein acts in a general manner to block 
splicing of exon 7, in the absence of SF2/ASF dependent 
ESE [12]. No matter which of these models is the real 
one, the result of the splicing factors action was obvious: 
only 20% of the SMN2 gene transcripts contain a 
message for the fl-SMN protein, while the remaining 80% 
are responsible for a truncated form. In SMA patients, the 
fl-SMN protein is synthesized in a small quantity, while the 
truncated protein is degraded and unable to sustain the 
motor neuron survival. 
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These molecular mechanisms indicated that SMN2 
gene could be a good target for SMA disease therapy, 
meaning the increase of fl-SMN protein level. Different 
compounds are tested in order to accomplish this aim. 
However, alternative strategies using neuroprotective 
agents, stem cells transplantation or gene therapy are 
ongoing. 
Enhancement of SMN expression 
The ability of SMN2 gene to encode for the fl-SMN 
protein has been hardly exploited, by several 
mechanisms: 
 
a.  Increasing the fl-SMN transcript level by 
activating SMN2 gene promoter 
Some researchers reported that the promoters of 
the SMN genes have similar positive regulatory elements 
[13]. This information was extremely useful in finding the 
compounds able to increase the fl-SMN2 transcript level 
and, in an implicit way, the normal fl-SMN protein quantity. 
It is well known that histone acetyltransferases (HATs) 
enhance the transcription through the chromatin 
relaxation, while the histonedeacetylases (HDACs) induce 
the transcriptional repression by chromatin condensation 
[14]. In this context, HDAC inhibitors became good 
candidates in finding a way to increase the fl-SMN level. 
For the first time, these kinds of compounds were used in 
2001: a revolutionary increase of fl-SMN2 transcript level 
could be noticed following the sodium butyrate treatment 
of SMA patients, derived cell lines and SMA knockout 
transgenic mice [15]. Additional researches indicated that 
the half-life of sodium butyrate does not recommend its 
use in clinical trials. Anyway, these studies concerning the 
effect of sodium butyrate on SMN gene expression were 
the beginning for new researches in testing the action of 
HDAC inhibitors compounds on SMN expression. 
A sodium butyrate derivate (sodium  4 
phenylbutyrate - PB) has been tested on fibroblast cells 
derived from SMA patients [16] and then in clinical trials 
[17,18]. The emerging conclusion was that PB improves 
motor neuron function in SMA type II patients, by 
enhancing the fl-SMN transcript and protein levels. 
Although patients with urea cycle disorders [19] tolerate 
well this compound, its clinical use in SMA is still reserved, 
because of its short half-life of approximately 1 hour. 
Another HDAC inhibitory compound with a 
promising effect in SMA treatment is hidroxyurea. In 
cultured lymphocytes from SMA patients, hidroxyurea is 
able to increase the ratio of full-length to truncated SMN 
messenger RNA, the SMN protein level and intranuclear 
gems number (the structures containing SMN protein) 
[20]. Based on this data, clinical trials were opened in 
United States [21] and Taiwan [22]. Preliminary results 
showed an increase of fl-SMN mRNA level at only 8 
weeks of treatment. 
The most studied HDAC inhibitor in SMA treatment 
is valproic acid (VPA) also known as 2 - propylpentanoic 
acid. This drug was already used in the treatment of 
epilepsy and with therapeutically indication in bipolar 
disorders. Taking into account that VPA is a fatty acid and 
a HDAC inhibitor, just like sodium butyrate, it was 
hypothesized that it may increase SMN2 mRNA level. If 
sodium butyrate has a short half-life of only six minutes in 
human serum, the VPA has the advantage of 8 to 10 
hours half-life. The administration of VPA in therapeutic 
doses (0.5–1000µM), on fibroblast lines in SMA patients, 
for a 16-hour period, has determined the increase of fl-
SMN2 mRNA level from 2 to 4 fold. As it was expected, a 
stronger response was obtained when VPA low doses 
(0.5-5µM) were administrated on fibroblast lines in SMA 
patients with more than two SMN2 copies. By testing the 
action of this drug on rat organotypic hippocampal slice 
cultures (often used for Central Nervous System disorders 
studies), it was proved that VPA also increases SMN level 
in the neuronal tissue [23,24]. It is presupposed that VPA 
action is mediated by binding AP1 and SP1 transcription 
factors through the human and rat SMN promoter [23]. 
The VPA effects on neurogenesis and astrocyte 
proliferation, as well as on increased levels of Bcl-2 and 
Bcl-x anti-apoptotic factors, were also discussed in 
researches involving type III like - SMA mouse models 
[25]. These in vitro and in vivo studies have encouraged 
the opening of VPA clinical trials. Consequently to the pilot 
trial which showed an increased SMN protein level in 
healthy carriers as well in SMA patients [26], four clinical 
trials with VPA and carnitine (to avoid the possible toxicity 
of the drug) have been started [27]. 
HDAC inhibitors from the second generation like 
Trichostatin A, SAHA, M344 benzamide, MS-275, m-
Carboxycinnamic acid, bis-Hydroxamide were included in 
several recent studies [28,29]. Of these compounds, 
SAHA seems to be the most promising drug for therapy, 
as it increases SMN levels at low concentrations, has a 
favorable profile citotoxicity and it is well tolerated [29].  
 
b.  Preventing the SMN2 exon 7 from skipping 
Researches regarding the molecular mechanism of 
SMA physiopathology revealed that the production of the 
SMN truncated protein is the result of an alternative 
splicing of exon 7 in the majority of patients. Preventing 
this exon from skipping is one of the most common ways 
to increase the full-length of SMN protein level. 
The first identified compound that helps in 
preventing splicing of the endogenous SMN2 exon 7 is 
sodium vanadate, an inhibitor of protein tyrosine 
phosphatases, alkalin phosphatases and ATPases. 
Among several signaling pathways modulators on splicing, 
only treatment with sodium vanadate (50-100µM) for 10 to 
24 hours showed an important increase in fl-SMN2 
mRNA. The treatment with 50µM sodium vanadate 
caused the highest amount of the fl- transcript, while a 
concentration over 100µM resulted in the cell’s death. The 
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long treatment period is explained by the time needed for 
cellular processes like transcription or phosphorylation. In 
this context, it is hypothesized that the phosphorylation of 
some cellular factors may be involved in SMN2 splicing 
process and that the most probable proteins influenced by 
sodium vanadate treatment are SR, snRNP and hnRNP 
[30]. 
The HDAC inhibitors have effects not only on 
chromatin relaxation, but also on SMN exon 7 retaining, 
as it could be noticed in the case of sodium butyrate 
treatment on lymphoid cell lines. According to this 
treatment, the SR protein induction was detected [15]. 
This dual action exerted on SMN protein level was also 
observed in the case of VPA and Trichostatin A. 
Aclarubicin, a drug from anthracylcine antibiotic 
class is frequently used in chemotherapy against solid 
tumors and leukemia. However, aclarubicin seems to 
significantly increase the gems number and the SMN level 
in a SMA I patient derived fibroblasts, by altering the 
splicing process. The high toxicity profile has embedded 
the use of this drug in treating SMA patients [31]. 
Trying to avoid the discovery of the potential 
therapeutic drugs that cannot cross the blood brain 
barrier, a recent research [32] has focused on the action 
of some polyphenol botanical compounds with known 
ability in passing this difficulty. Curcumin, resveratrol and 
epigallocatechin galate were previously reported to have 
some modifying actions in neurodegenerative diseases 
[33]. An increase in fl-SMN transcripts and protein levels 
was noticed after the administration of these compounds 
in cultures of SMA derived fibroblast cells. Additionally, it 
seems that curcumin up-regulate some genes encoding 
for SR proteins, essentially in splicing process. 
Among natural or synthesized compounds, physical 
exercises are reported to be involved in the SMN2 splicing 
regulation, probably by modifying the expression pattern 
of pre-mRNA splicing factors in motoneurons [34]. 
Another study based on type 2 SMA mouse model proved 
that physical exercises have benefic effects in motor 
neuron protection, acceleration of muscle maturation and 
lifespan gain through the NMDA–receptor activity 
modulation [35]. A combined therapy of drugs and regular 
physical exercises is thought to improve clinical signs in 
SMA patients. 
[46]. 
revealed a small 
impro
benefactor effects of this drug. At this moment, two 
 
c.  Stabilizing SMN Protein 
In order to identify the compounds able to stabilize 
the SMN protein, by acting at the translational level, a high 
throughput screening of approximately 47000 compounds 
with potential effect on SMN protein was performed. Only 
indoprofen increases the SMN protein level in the treated 
fibroblast cells with about 13 percent, reported to 
untreated cells [36]. Moreover, as a result of indoprofen 
treatment, the number of gems was enhanced in vitro and 
a reduced embryonic lethality was noticed in SMA mutant 
mice.  
SMN stabilizing protein compounds are also 
aminoglycosides. This class of antibiotics have in vitro 
capacities to suppress premature stop mutations in some 
genes (e.g. CFTR [37] and dystrophin genes [38]) and to 
affect the translation termination process, by altering the 
conformation of ribosomal decoding site [39]. Based on 
these findings, a research group reported an important 
increase of SMN protein level of fibroblast treatment with 
tobramycin and amikacin [40]. Other six aminoglycosides 
which were found to increase SMN protein level in 
fibroblast cells [41] may be used for therapeutic purposes. 
There are also studies indicating that proteasome 
inhibitors may have a benefic effect on SMN protein 
stability [42]. It is already known that the 
ubiquitin/proteasome pathway has an important role in the 
proteolysis of intracellular proteins. By using pulse-chase 
analysis, it was confirmed that SMN protein is 
ubiquitinated and degraded by the ubiquitin/proteasome 
system [43].  
Neurotrophic, neuroprotective and 
anabolic agents’ administration 
Neurotrophic factors have been referred to be good 
candidates for therapeutic strategies of several motor 
neurons diseases, based on the ability to slow down motor 
neuron death and axon degeneration [44]. Cardiotrophin-1 
is a cytokine from interleukin-6 family, with known benefic 
effects on survival of motor neurons during embryonic 
period [45]. The cardiotrophin-1 delivery to SMA mutant 
mice revealed that the protective role for proximal and 
distal motoneurons is also present in postnatal period 
Neuroprotective agents were proposed for clinical 
trials in SMA, following the in vitro and in vivo studies. 
Because a hypothesis regarding SMA pathogenesis 
includes glutamate citotoxicity, factors with anti-glutamate 
action have been tested in order to improve the motor 
skills and life expectancy. Gabapentin is an excitatory 
amino acid neurotransmitter with neuroprotective 
properties, proposed to have therapeutic effects for 
Amyotrophic Lateral Sclerosis (ALS). Two clinical trials 
with gabapentin were developed for patients with SMA 
types II and III, for a one-year period. If the first 
gabapentin study (developed on 84 SMA patients) has not 
revealed any potential therapeutic effects [47], the second 
one (applied on 120 patients) 
vement of muscle strength [48]. 
Another anti-glutamate factor is riluzole, a 
compound with neuroprotective effects tested in a SMA 
mutant mouse model [49]. The first clinical trial of riluzole 
in SMA patients was started in 2003 [50] and enrolled 10 
SMA type I patients. The authors of this study concluded 
that it is safe to use riluzole in infants, but a more 
statistical powerful study is needed to ascertain the Journal of Medicine and Life Vol. 3, No.1, January-March 2010 
riluzole trials are ongoing on SMA type I patients in USA 
and in France [51]. 
Anabolic agents such as albuterol (also known as 
salbutamol) were reported to have significant results in 
clinical state improvement. Myometry, forced vital capacity 
and lean body mass were increased after 6-months of oral 
administration [52]. Starting from these clinical findings, a 
few years later, another research group studied these 
effects of the drug and reported an increase of SMN 
mRNA and protein level in fibroblast cells derived from 
SMA patients [53]. It is thought that the salbutamol is 
acting on SMN protein through the influence of the SMN2 
exon 7 splicing event. 
It was recently reported that Follistatin [54] is an 
anabolic agent with an ability to increase muscle mass, to 
improve motor neurons’ function and to prolong life 
survival, in SMA mutant mice. Taking into account that the 
SMN protein level was not increased by follistatin 
administration, it was suggested that this glycoprotein 
exerts its beneficial effects by a SMN independent 
mechanism. It is thought that follistatin is acting, at least in 
part, through a myostatin (a TGF-B family member) 
pathway, a negative regulator of muscle mass. The over 
expression of follistatin in myostatin null mice, results also 
in an enhancement of muscle mass, suggesting the 
existence of additional pathways or acting mechanisms 
[55]. 
A combined therapy of neurotrophic, 
neuroprotective or anabolic agents may lead to the 
improvement of SMA phenotype and, in an implicit 
manner, to the lifespan duration. 
 
Stem cell transplantation and gene therapy 
Stem cell transplantation and gene therapy 
represent a promising future in the treatment of motor 
neuron diseases, including SMA. It is known that neuronal 
stem cell transplantation can lead to an improvement of 
motor neuron disease phenotype, through different 
mechanisms, such as replacement of non-neuronal cells 
[56], delivery of neuroprotective factors [57] or reduction 
of toxic compounds [58]. For the first time, stem cells 
transplantation was used in a SMA model as putative 
therapeutic pathway in 2008 [59]. The motor neuron 
function improvement and survival of SMA mice led to the 
conclusion that neural stem cells transplantation has 
positive effects on SMA disease phenotype. 
Lesbordes was reported to have conducted the first 
gene therapy study on SMA in 2003, [46]. He used the 
intra-muscular injection with an adenoviral vector 
expressing cardiotrophin-1, whose effects were discussed 
previously in this paper. The method had been tested few 
years earlier [60], when cardiotrophin-1 appeared to be a 
protective factor in progressive motor neuronopathy model 
mice. In 2004, a new gene therapy study was reported: a 
lentivector developed from infectious equine anemia virus 
was used in gene transfer in SMA mice, consequently in in 
vitro testing. The SMN lentivector was injected in two days 
of age SMA mice at the level of the voluntary muscles. 
Following this therapy, the SMA mice life expectancy was 
increased with 3 to 5 days and a motor neuron death 
reduction could be recorded [61]. 
Remarkable results for SMA potential therapy were 
obtained by using RNA strategies. The enhancing of exon 
7 incorporation in SMN message was found to be a 
successful strategy in the increase of SMN protein level, 
but drugs such as sodium vanadate, sodium butyrate and 
aclarubicin were not recommended because of their short 
half-life or toxicity. A bifunctional antisense 
oligonucleotides strategy was developed in order to 
increase  SMN2 gene expression [62].  The antisense 
oligonucleotides (about 20 nucleotides length) are 
complementary to SMN2 exon 7 sequence but also 
contain non-complementary tails, able to bind splicing 
factors and to stimulate the natural splicing reaction. 
Applying this strategy, additional to the action on SMN2 
exon 7 splicing, a partial restoration of gems number in 
SMA fibroblast cells could be observed. In vivo, delivery of 
bifunctional RNAs was possible by using plasmid-based 
and rAAV recombinant adeno-associated virus vectors 
[63]. The advantage of rAAV vectors is the high tropism 
for myocites and neuronal cells and the retrograde 
transport to neurons after the intramuscular injection. An 
improvement of the antisense oligonucleotides strategy 
was the use of modified U7snRNA, as vehicle for SMN 
antisense, RNA complementary to the 3’splice site of SMN 
exon 8 [64]. This way, the researchers were able to 
identify anti SMN U7snRNAs that can alter the splicing 
process and stimulate the SMN2 exon 7 retaining. 
Compared to the others antisense oligonucleotides 
strategies that use chemical modified RNAs, the SMN 
U7snRNAs provide the advantage of the continuous 
delivery in the cell and the increased half-life of the RNAs. 
Another RNA strategy for preventing SMN2 exon7 
from skipping is known as trans – splicing system. Trans-
splicing is a natural but rare process that has been 
recently induced in therapeutic assays for cystic fibrosis 
[65 66 ] or Alzheimer disease [ ]. This strategy is based on 
the competition for splices sites between endogenous 
RNA (mutant) and the therapeutic RNA (able to provide 
the correct RNA sequence through a trans splicing 
process). Initially, plasmids and rAAVs were used for 
delivery of trans splicing RNAs, in order to restore small 
nuclear ribonucleoprotein (snRNP) assembly in vitro [67]. 
As this method had no results in vivo, a new system was 
developed: a single vector that co-expresses the trans 
splicing RNA. This way, antisense RNA is able to increase 
the snRNP assembly and SMN level protein in vitro as 
well as in vivo [68]. Although the regulatory networks for 
this constructs are not yet clarified, the results are 
promising and there is a hope of improving therapeutic 
strategies for SMA, life expectancy and quality of life for 
patients. 
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Conclusions  the limiting factors. A special care is needed when results 
obtained in animal models are extrapolated in clinical trials 
on humans, taking into account the genetics and 
physiopathological differences between species. The stem 
cell and gene therapy give promising results, but the 
confirmation for a drug and its way to delivery, are still 
being waited for. 
A large spectrum of compounds that act through 
various mechanisms were tested in order to identify a 
therapeutically drug in treating spinal muscular atrophy 
disease. However, no compound is currently available in 
SMA therapy, as toxicity and half-life duration are some of  
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